At Leafwell, we are dedicated to advancing the understanding and application of medical cannabis. With one of the largest patient databases in the world, we are committed to contributing to research in the medical cannabis field to improve patient outcomes and access to lifesaving care.
Our latest study, published earlier this week, draws on data from 2019-2023 and provides crucial insights into medical cannabis use among individuals under 21.
Here are some of the key findings from our study:
👥 Minors vs. Young Adults: Our research reveals that minors constitute a small percentage (around 1%) of medical cannabis users. Within our sample, only 5.7% were minors, with the remaining 94.3% being 18-to-20-year-olds.
📍 States with the Most Minor Patients: The highest counts of minor patients were found in California, Ohio, and Oregon. When considering rates per 100,000 population, Maine, Oregon, and New Hampshire show the highest prevalence of minor patients.
🏥 Medical Conditions: Anxiety emerged as the most commonly reported primary condition, followed by chronic pain, and nausea/vomiting. Notably, higher percentages of young adults reported chronic pain, depression, and insomnia compared to minors. Conversely, conditions such as cancer, epilepsy, PTSD, and other miscellaneous conditions were reported at higher percentages among minors.
🔬 The Need for Further Research: There remains a significant need for continued research to address gaps in pediatric-specific evidence. Understanding how medical cannabis affects individuals under 20 is crucial for improving patient care and informing regulatory frameworks.
Leafwell is proud to fund and support research efforts that pave the way for better healthcare solutions and innovations.
Read more here: https://lnkd.in/gzAQbVWn
Mitchell L. Doucette, PhD, MS
Dr. June Chin
Emily Fisher
Luke Macfarlan
Dipak Hemraj
#MedicalCannabis #PediatricResearch #LeafwellResearch